SAN DIEGO and TORONTO, November 3, 2025 — Aptose Biosciences Inc. (TSX: APS), a clinical-stage precision oncology company, announced that new data from its ongoing TUSCANY trial evaluating tuspetinib (TUS) in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia (AML) has been selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, scheduled for December 6–9, 2025, in Orlando, Florida. The abstract, titled “TUSCANY Study Demonstrates Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Ineligible for Induction Chemotherapy,” underscores the growing therapeutic promise of Aptose’s lead oral kinase inhibitor in frontline AML treatment.

Science Significance

Tuspetinib (TUS) represents a new generation of oral kinase inhibitors engineered for selective, multi-target inhibition in hematologic malignancies. The TUSCANY study explores its potential as part of a triplet regimen with venetoclax and azacitidine, aiming to improve response rates and survival outcomes in patients ineligible for intensive induction chemotherapy. This innovative approach seeks to enhance anti-leukemic activity while maintaining manageable safety profiles, potentially redefining the treatment paradigm for newly diagnosed AML patients with limited therapeutic options. The ASH selection validates the scientific merit and clinical relevance of Aptose’s precision oncology platform.

Regulatory Significance

The presentation at ASH highlights regulatory progress for tuspetinib, which has already demonstrated clinical safety and efficacy signals across Phase 1 and ongoing Phase 1/2 studies. Selection by the world’s leading hematology congress signifies recognition by the scientific and regulatory community of the drug’s potential advancement toward later-stage trials. Aptose’s consistent compliance with Good Clinical Practice (GCP) and international trial standards reinforces confidence in the quality of data supporting future regulatory submissions to agencies like the FDA and Health Canada.

Business Significance

The ASH data acceptance enhances Aptose’s corporate visibility and investor confidence. The company continues to leverage its precision oncology pipeline to attract collaborations and partnerships that can expedite the commercial pathway of tuspetinib. With the AML therapeutic market expanding rapidly due to increased incidence in older adults, Aptose is strategically positioned to compete in a multi-billion-dollar market through targeted therapies that address unmet clinical needs. The recognition from ASH serves as a business milestone that underscores Aptose’s clinical momentum and R&D credibility within the oncology sector.

Patients’ Significance

For patients with newly diagnosed AML who cannot undergo intensive chemotherapy, the tuspetinib-based triplet regimen represents a potential breakthrough. The therapy aims to extend survival, improve remission rates, and reduce treatment toxicity, providing a more tolerable and effective alternative for elderly or high-risk patients. The TUSCANY trial’s promising early data could pave the way for accessible, oral-based precision treatments, offering renewed hope and quality of life for AML patients with limited treatment options.

Policy Significance

The inclusion of tuspetinib data at a premier medical meeting reinforces the importance of continued global investment in oncology innovation and the role of collaborative research frameworks. With governments and regulatory agencies prioritizing accelerated pathways for breakthrough oncology drugs, Aptose’s work aligns with emerging policy trends promoting early access to life-saving therapies. The TUSCANY study’s progress reflects how clinical-stage biotech companies can complement public health goals by addressing rare and aggressive malignancies through innovation and ethical clinical research.

The selection of Aptose’s tuspetinib data for presentation at ASH 2025 marks a pivotal moment in the company’s pursuit of next-generation precision oncology treatments for AML. Backed by strong preclinical rationale, clinical validation, and regulatory alignment, tuspetinib stands as a beacon of progress in hematologic cancer therapeutics. As Aptose continues to advance its triplet therapy platform, the data presented at ASH may define a new frontier in AML management, setting the stage for future Phase 3 evaluation and potential regulatory advancement.

Source: Aptose Biosciences Inc. press release